Extending healthy, human life
The Cure Is Now supports Dr. Aubrey de Grey’s research which is conducted under the auspices of SENS. SENS Foundation works to develop, promote and ensure widespread access to rejuvenation biotechnologies which comprehensively address the disabilities and diseases of aging. Dr. de Grey’s long term plans are to design and establish robust mouse rejuvenation and then apply this research to humans.
Dr. de Grey will eventually require a staff of 100 people.
Cost: The budget required for his staffing and equipment needs are $20MM over the next three-years and $40MM over the next 5.
Telomeres are specialized DNA structures at the ends of chromosomes that protect them from damage. With age, telomeres can get shorter, which could prevent cells from dividing or cause other cellular dysfunction. This process of shortening telomeres is thought to contribute to the emergence of age-related diseases. Bill Andrews is working on developing drugs that can slow, stop or even reverse this process of shortening. These drugs could potentially be used as treatments for age-related diseases and could greatly improve the quality of life for elderly individuals.
Currently, 13 people are working on developing these drugs, but another 52 are required to bring the drugs to clinical trials
Genetics and Healthy Lifespan:
Brandon Milholland studies somatic mutations, in which individual cells in the body become mutated. These mutations may give rise to age-related diseases and cancer. Establishing the correlation between somatic mutation and aging could help develop treatments to extend healthy lifespan.
Requirements for this research include cell lines, media and incubators, sequencing machines and reagents, and computational resources to analyze the data.
Stem Cell Therapy/Age-Related Disease:
Within the human body, dead or damaged cells are constantly being replaced from niches of stem cells. With age, these niches may be depleted, leading to frailty, disease and impaired wound healing in the elderly. Dr. John Schloendorn is working on developing stem cell therapies that could cure age-related diseases and greatly improve quality of life for the elderly.
To develop the first cure, a team of 10 people would be required, as would a fully equipped molecular biology lab.